metronidazol baxter viaflo innrennslislyf, lausn 5 mg/ml
baxter medical ab - metronidazolum inn - innrennslislyf, lausn - 5 mg/ml
uromitexan stungulyf, lausn 100 mg/ml
baxter medical ab* - mesnum inn - stungulyf, lausn - 100 mg/ml
caelyx pegylated liposomal
baxter holding b.v. - doxórúbicín hýdróklóríð - sarcoma, kaposi; multiple myeloma; ovarian neoplasms; breast neoplasms - Æxlishemjandi lyf - einungis mjög liposomal er ætlað:eitt og sér fyrir sjúklinga með brjóstakrabbamein, þar sem það er aukin hjarta hættu;fyrir meðferð háþróaður krabbamein í konum sem hafa mistekist fyrsta lína platínu-byggt lyfjameðferð meðferð;ásamt bortezomib fyrir meðferð framsækið margar forráðamenn í sjúklingar sem hafa fengið að minnsta kosti einn áður en meðferð og hver hefur þegar tekið eða eru ekki við hæfi fyrir beinmerg grætt;fyrir meðferð aids-tengjast kaposissarkmein (ksxp) í sjúklinga með litla cd4 telja (.
holoxan innrennslisstofn, lausn 500 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 500 mg
holoxan innrennslisstofn, lausn 2000 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 2000 mg
holoxan innrennslisstofn, lausn 1000 mg
baxter medical ab* - ifosfamidum inn - innrennslisstofn, lausn - 1000 mg
sendoxan tafla 50 mg
baxter medical ab* - cyclophosphamidum inn - tafla - 50 mg
sendoxan stungulyfsstofn, lausn 1 g
baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 1 g
sendoxan stungulyfsstofn, lausn 500 mg
baxter medical ab* - cyclophosphamidum inn - stungulyfsstofn, lausn - 500 mg
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxórúbicín hýdróklóríð - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - Æxlishemjandi lyf - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).